Clinical Trials

OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy


Study ID
Georgetown 2017-1535 CA209-8CL

NCT Number
NCT03487666 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0611

Principle Investigator
Dr. Deena Graham

Phase
II

Sponsor
Georgetown


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now